Physician profile
Abelardo Mares
NPI 1780821868
$1,636.93
in general payments reported to CMS, 2019-2025
15 companies · $813 in 2025
The $813 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $397 · 2023: $371 · 2024: $55.90 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $385.11 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $278.83 | 2022-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $216.26 | 2025 | |
| Abbvie INC. | $161.81 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $153.20 | 2022-2023 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $130.16 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $85.64 | 2022 | |
| Merck Sharp & Dohme LLC | $53.98 | 2023 | Belsomra |
| Glaxosmithkline, LLC. | $30.42 | 2024-2025 | Shingrix |
| Axsome Therapeutics, INC. | $28.51 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $26.83 | 2025 | Cobenfy |
| Corium, LLC | $23.06 | 2023 | Azstarys |
| Harmony Biosciences LLC | $22.58 | 2022 | |
| Vanda Pharmaceuticals INC. | $21.40 | 2025 | Fanapt |
| Alkermes, INC. | $19.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abelardo Mares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.